Delivery Order SPE2DB20D3303-SPE2DB25FA2DR
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $43,473.13 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60 count) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded contract supporting federal pharmaceutical procurement needs. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $7,386.55 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count) on August 20, 2025, with an ultimate completion date of August 21, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $7,764.93 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) with a completion date of August 20, 2025. This competitive award, issued on August 19, 2025, carries firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The place of performance is AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a $2,500.53 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count) on August 4, 2025, with an ultimate completion date of August 5, 2025. This non-set-aside contract was competitively awarded and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The delivery order represents a relatively small-value transaction within AmerisourceBergen's broader federal...
- The Defense Logistics Agency awarded a delivery order valued at $17,620.78 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed pricing and represents a continuation of pharmaceutical supply services under AmerisourceBergen's broader federal contract portfolio. The product will be delivered to the company's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $11,258.73 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count packages). This firm fixed price contract, awarded on August 19, 2025, with completion expected by August 20, 2025, carries no set-aside designation and was competitively awarded. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a routine...
- The Defense Logistics Agency awarded a $13,321.78 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Otezla 30 mg tablets (60-count packages) on July 24, 2025, with an ultimate completion date of July 25, 2025. This is a non-set-aside competitive award issued as a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.999 billion through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a $36,477.84 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Otezla 30 mg tablets (60-count units). The contract is a firm fixed price delivery order with an ultimate completion date of July 30, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $1,918.71 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count) on August 15, 2025, with an ultimate completion date of August 18, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under...
- The Defense Logistics Agency awarded a $31,530.56 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Otezla 30 mg tablets (60-count packages). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 28, 2025. The delivery order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and primary...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA2DRDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,707.42 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. As a primary pharmaceutical prime vendor for the Defense Logistics Agency, AmerisourceBergen provides comprehensive medical supply support to military and veteran healthcare systems, including specialty medications, brand-name and generic drugs, and related medical commodities across multiple therapeutic domains. The company's federal procurement portfolio demonstrates consistent capability to fulfill competitively awarded orders ranging from modest to substantial values, supporting critical healthcare requirements across the Department of Defense and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.7k | 8/4/25 |